131 related articles for article (PubMed ID: 36933996)
21. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
22. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
[TBL] [Abstract][Full Text] [Related]
23. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
24. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.
Saleeb RM; Brimo F; Farag M; Rompré-Brodeur A; Rotondo F; Beharry V; Wala S; Plant P; Downes MR; Pace K; Evans A; Bjarnason G; Bartlett JMS; Yousef GM
Am J Surg Pathol; 2017 Dec; 41(12):1618-1629. PubMed ID: 28984673
[TBL] [Abstract][Full Text] [Related]
25. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
26. Papillary renal cell carcinoma: current and controversial issues.
Angori S; Lobo J; Moch H
Curr Opin Urol; 2022 Jul; 32(4):344-351. PubMed ID: 35674688
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA profiles classify papillary renal cell carcinoma subtypes.
Wach S; Nolte E; Theil A; Stöhr C; T Rau T; Hartmann A; Ekici A; Keck B; Taubert H; Wullich B
Br J Cancer; 2013 Aug; 109(3):714-22. PubMed ID: 23799849
[TBL] [Abstract][Full Text] [Related]
29. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
30. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.
Kovac M; Navas C; Horswell S; Salm M; Bardella C; Rowan A; Stares M; Castro-Giner F; Fisher R; de Bruin EC; Kovacova M; Gorman M; Makino S; Williams J; Jaeger E; Jones A; Howarth K; Larkin J; Pickering L; Gore M; Nicol DL; Hazell S; Stamp G; O'Brien T; Challacombe B; Matthews N; Phillimore B; Begum S; Rabinowitz A; Varela I; Chandra A; Horsfield C; Polson A; Tran M; Bhatt R; Terracciano L; Eppenberger-Castori S; Protheroe A; Maher E; El Bahrawy M; Fleming S; Ratcliffe P; Heinimann K; Swanton C; Tomlinson I
Nat Commun; 2015 Mar; 6():6336. PubMed ID: 25790038
[TBL] [Abstract][Full Text] [Related]
31. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
[TBL] [Abstract][Full Text] [Related]
32. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
Singh NP; Vinod PK
Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
[TBL] [Abstract][Full Text] [Related]
33. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
Zhu B; Poeta ML; Costantini M; Zhang T; Shi J; Sentinelli S; Zhao W; Pompeo V; Cardelli M; Alexandrov BS; Otlu B; Hua X; Jones K; Brodie S; Dabrowska ME; Toro JR; Yeager M; Wang M; Hicks B; Alexandrov LB; Brown KM; Wedge DC; Chanock S; Fazio VM; Gallucci M; Landi MT
Nat Commun; 2020 Jun; 11(1):3096. PubMed ID: 32555180
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
35. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
36. Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells.
Saleeb RM; Farag M; Ding Q; Downes M; Bjarnason G; Brimo F; Plant P; Rotondo F; Lichner Z; Finelli A; Yousef GM
Am J Pathol; 2019 Oct; 189(10):2046-2060. PubMed ID: 31381885
[TBL] [Abstract][Full Text] [Related]
37. Screening and identification of key biomarkers of papillary renal cell carcinoma by bioinformatic analysis.
Xu Y; Kong D; Li Z; Qian L; Li J; Zou C
PLoS One; 2021; 16(8):e0254868. PubMed ID: 34358255
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M; Rioux-Leclercq N; Meylan M; Dauvé J; Passot C; Spirina-Menand E; Flippot R; Fromont G; Gravis G; Geoffrois L; Chevreau C; Rolland F; Blanc E; Lefort F; Ravaud A; Gross-Goupil M; Escudier B; Negrier S; Albiges L
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935564
[TBL] [Abstract][Full Text] [Related]
39. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases.
Han G; Yu W; Chu J; Liu Y; Jiang Y; Li Y; Zhang W
Pathol Res Pract; 2017 Jan; 213(1):1-6. PubMed ID: 27931799
[TBL] [Abstract][Full Text] [Related]
40. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
